Paul Tudor Jones Biotechnology

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
REGN Regeneron Pharmaceuticals, Inc.	$74.9B	$20.4 Million 0.08% of portfolio	28,570	Q4 2024 Reduced 24.12%
RPRX Royalty Pharma PLC	$14.7B	$18.8 Million 0.07% of portfolio	735,027	Q4 2024 Added 44.48%
MRNA Moderna, Inc.	$12.1B	$14.7 Million 0.06% of portfolio	353,865	Q4 2024 Added 131.14%
NVO Novo Nordisk A S	$205B	$10.5 Million 0.04% of portfolio	122,042	Q4 2024 Added 757.82%
UTHR United Therapeutics Corp	$14.6B	$7.9 Million 0.03% of portfolio	22,387	Q4 2024 Added 139.54%
BMRN Biomarin Pharmaceutical Inc	$13.2B	$6.55 Million 0.03% of portfolio	99,725	Q4 2024 Added 7.5%
INCY Incyte Corp	$16.3B	$6.42 Million 0.03% of portfolio	92,915	Q4 2024 Added 238.19%
VRTX Vertex Pharmaceuticals Inc	$123B	$3.81 Million 0.02% of portfolio	9,463	Q4 2024 New
NUVL Nuvalent, Inc.	$3.22B	$3.62 Million 0.01% of portfolio	46,263	Q4 2024 New
MDGL Madrigal Pharmaceuticals, Inc.	$5.84B	$3.19 Million 0.01% of portfolio	10,327	Q4 2024 New
ADPT Adaptive Biotechnologies Corp	$1.18B	$2.75 Million 0.01% of portfolio	458,488	Q4 2024 Reduced 11.11%
EXEL Exelixis, Inc.	$12.5B	$2.73 Million 0.01% of portfolio	82,127	Q4 2024 Reduced 35.25%
CORT Corcept Therapeutics Inc	$6.49B	$2.68 Million 0.01% of portfolio	53,169	Q4 2024 New
SRRK Scholar Rock Holding Corp	$2B	$2.68 Million 0.01% of portfolio	61,895	Q4 2024 Added 123.99%
PTCT Ptc Therapeutics, Inc.	$3.95B	$2.13 Million 0.01% of portfolio	47,151	Q4 2024 Added 22.01%
TBPH Theravance Biopharma, Inc.	$624M	$1.85 Million 0.01% of portfolio	196,578	Q3 2024 Added 1.45%
FOLD Amicus Therapeutics, Inc.	$2.66B	$1.4 Million 0.01% of portfolio	148,868	Q4 2024 Added 0.35%
VERA Vera Therapeutics, Inc.	$809M	$1.35 Million 0.01% of portfolio	31,843	Q4 2024 Added 30.09%
ACAD Acadia Pharmaceuticals Inc	$3.17B	$1.32 Million 0.01% of portfolio	71,680	Q4 2024 Reduced 23.26%
ARWR Arrowhead Pharmaceuticals, Inc.	$2B	$1.25 Million 0.0% of portfolio	66,573	Q4 2024 Added 6.65%
CDMO Avid Bioservices, Inc.	$776M	$1.25 Million 0.0% of portfolio	101,192	Q4 2024 Added 757.34%
CPRX Catalyst Pharmaceuticals, Inc.	$2.35B	$1.24 Million 0.0% of portfolio	59,552	Q4 2024 New
EWTX Edgewise Therapeutics, Inc.	$1.65B	$1.17 Million 0.0% of portfolio	43,809	Q4 2024 Added 23.01%
CDXC Chroma Dex Corp.	$385M	$1.16 Million 0.0% of portfolio	217,568	Q4 2024 New
GERN Geron Corp	$665M	$1.06 Million 0.0% of portfolio	298,660	Q4 2024 New
XERS Xeris Biopharma Holdings, Inc.	$521M	$1.03 Million 0.0% of portfolio	305,186	Q4 2024 Reduced 39.85%
DYN Dyne Therapeutics, Inc.	$705M	$1.02 Million 0.0% of portfolio	43,264	Q4 2024 Reduced 14.3%
MIRM Mirum Pharmaceuticals, Inc.	$1.75B	$990,000 0.0% of portfolio	23,966	Q4 2024 New
AKRO Akero Therapeutics, Inc.	$2.28B	$967,000 0.0% of portfolio	34,794	Q4 2024 Added 0.46%
AGIO Agios Pharmaceuticals, Inc.	$1.95B	$938,000 0.0% of portfolio	28,553	Q4 2024 New
ARQT Arcutis Biotherapeutics, Inc.	$824M	$896,000 0.0% of portfolio	64,334	Q4 2024 Added 206.88%
RYTM Rhythm Pharmaceuticals, Inc.	$3.06B	$852,000 0.0% of portfolio	15,245	Q4 2024 New
CLDX Celldex Therapeutics, Inc.	$962M	$822,000 0.0% of portfolio	32,545	Q4 2024 New
VCYT Veracyte, Inc.	$2.49B	$805,000 0.0% of portfolio	20,342	Q4 2024 Reduced 50.23%
TARS Tarsus Pharmaceuticals, Inc.	$1.19B	$768,000 0.0% of portfolio	13,880	Q4 2024 New
TVTX Travere Therapeutics, Inc.	$1.37B	$752,000 0.0% of portfolio	43,213	Q4 2024 Added 13.29%
BCRX Biocryst Pharmaceuticals Inc	$1.6B	$747,000 0.0% of portfolio	99,450	Q4 2024 New
VRDN Viridian Therapeutics, Inc.\De	$619M	$735,000 0.0% of portfolio	38,367	Q4 2024 Added 2.97%
CRSP Crispr Therapeutics Ag	$3.43B	$721,000 0.0% of portfolio	18,337	Q4 2024 Reduced 60.98%
BPMC Blueprint Medicines Corp	$5.77B	$706,000 0.0% of portfolio	8,100	Q4 2024 New
ARDX Ardelyx, Inc.	$829M	$654,000 0.0% of portfolio	126,530	Q4 2024 New
RCUS Arcus Biosciences, Inc.	$786M	$639,000 0.0% of portfolio	42,968	Q4 2024 Reduced 5.88%
MDXG Mimedx Group, Inc.	$954M	$576,000 0.0% of portfolio	59,896	Q4 2024 New
INVA Innoviva, Inc.	$1.25B	$548,000 0.0% of portfolio	31,617	Q4 2024 Reduced 0.68%
CDXS Codexis, Inc.	$199M	$507,000 0.0% of portfolio	106,365	Q4 2024 Added 83.09%
MNKD Mannkind Corp	$1.37B	$503,000 0.0% of portfolio	78,382	Q4 2024 Reduced 44.98%
AVXL Anavex Life Sciences Corp.	$617M	$494,000 0.0% of portfolio	46,044	Q4 2024 New
LQDA Liquidia Corp	$997M	$454,000 0.0% of portfolio	38,619	Q4 2024 New
QURE Uni Qure N.V.	$614M	$437,000 0.0% of portfolio	24,784	Q4 2024 Added 5.86%
BEAM Beam Therapeutics Inc.	$1.85B	$411,000 0.0% of portfolio	16,575	Q4 2024 Reduced 49.49%

Shares Options

Paul Tudor Jones

Paul Tudor Jones is the founder and CEO of Tudor Investment Corp, a successful investment firm that focuses on macro investing. Jones is known for his expertise in macro investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Paul Tudor Jones's portfolio

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account